# A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.

> **NCT05689164** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 7 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **BIOLOGICAL:** fordadistrogene movaparvovec

## Key facts

- **NCT ID:** NCT05689164
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-13
- **Primary completion:** 2025-09-24
- **Final completion:** 2025-09-24
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in 1 combined study: C3391003
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05689164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05689164, "A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05689164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*